EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-14.69%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$180M
AUM Growth
+$180M
(-9.5%)
Cap. Flow
+$15.9M
Cap. Flow
% of AUM
8.8%
Top 10 Holdings %
Top 10 Hldgs %
68.28%
Holding
73
New
12
Increased
20
Reduced
16
Closed
16
Top Buys
| 1 |
GSK
GSK
|
$9.25M |
| 2 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$5.28M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$5.26M |
| 4 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$4.05M |
| 5 |
AMRN
Amarin Corp
AMRN
|
$3.64M |
Top Sells
| 1 |
Merck
MRK
|
$7.86M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$3.39M |
| 3 |
Abbott
ABT
|
$3.16M |
| 4 |
Medtronic
MDT
|
$2.65M |
| 5 |
AnaptysBio
ANAB
|
$2.25M |
Sector Composition
| 1 | Healthcare | 77.95% |
| 2 | Industrials | 10.36% |
| 3 | Real Estate | 0.53% |
| 4 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
| $20.5M | 11.12% | 563,429 +144,150 | +34% | +$5.26M |
|
|
2
GSK
GSK
$79.9B
| $20.4M | 11.04% | 529,484 +240,200 | +83% | +$9.25M |
|
|
RCM
3
DELISTED
R1 RCM Inc. Common Stock
RCM
| $18.7M | 10.11% | 2,349,306 +664,219 | +39% | +$5.28M |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $17.2M | 9.31% | 1,263,407 +267,707 | +27% | +$3.64M |
|
5
Sanofi
SNY
$121B
| $13.3M | 7.2% | 306,242 +25,370 | +9% | +$1.1M |
|
|
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
| $9.1M | 4.93% | 552,053 +23,061 | +4% | +$380K |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $8.4M | 4.55% | 232,790 +112,079 | +93% | +$4.05M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $6.05M | 3.27% | 36,492 -11,600 | -24% | -$1.92M |
|
9
Danaher
DHR
$147B
| $4.94M | 2.67% | 47,804 +12,200 | +34% | +$1.26M |
|
|
ABMD
10
DELISTED
Abiomed Inc
ABMD
| $4.53M | 2.45% | 13,939 +10,520 | +308% | +$3.42M |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $4.42M | 2.39% | 40,494 -1,700 | -4% | -$186K |
|
12
argenx
ARGX
$43.6B
| $3.67M | 1.99% | 38,224 +14,670 | +62% | +$1.41M |
|
|
13
Merck
MRK
$210B
| $3.53M | 1.91% | 45,800 -102,000 | -69% | -$7.86M |
|
14
The Ensign Group
ENSG
$9.91B
| $3.32M | 1.8% | 85,575 -49,080 | -36% | -$1.91M |
|
|
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.17M | 1.72% | 81,371 -38,000 | -32% | -$1.48M |
|
|
TLGT
16
DELISTED
Teligent, Inc
TLGT
| $3.08M | 1.67% | 2,247,476 +135,378 | +6% | +$185K |
|
|
TSRO
17
DELISTED
TESARO, Inc.
TSRO
| $2.67M | 1.45% | +36,000 | New | +$2.67M |
|
|
18
Abbott
ABT
$231B
| $2.27M | 1.23% | 31,400 -43,700 | -58% | -$3.16M |
|
19
Fate Therapeutics
FATE
$120M
| $2.12M | 1.15% | +165,000 | New | +$2.12M |
|
20
Qiagen
QGEN
$10.1B
| $1.91M | 1.03% | +55,300 | New | +$1.91M |
|
21
Illumina
ILMN
$15.8B
| $1.54M | 0.84% | +5,148 | New | +$1.54M |
|
|
GHDX
22
DELISTED
Genomic Health, Inc.
GHDX
| $1.54M | 0.83% | +23,866 | New | +$1.54M |
|
23
Viatris
VTRS
$12.3B
| $1.51M | 0.82% | +55,000 | New | +$1.51M |
|
|
DCPH
24
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.46M | 0.79% | +69,700 | New | +$1.46M |
|
25
Apellis Pharmaceuticals
APLS
$3.48B
| $1.41M | 0.76% | 106,880 +6,585 | +7% | +$86.9K |
|